相关实验视频

Updated: Jun 4, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

在CAR T细胞中CCR5和IL-12的共同表达通过重编程固体瘤中的瘤微环境来提高抗瘤功效

Yonggui Tian^1,2, Liubo Zhang¹, Yu Ping¹

¹Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.

Cancer immunology, immunotherapy : CII

|January 3, 2025

概括

针对固体瘤的工程化模拟抗原受体 (CAR) T 细胞显示出更好的透和有效性. 同时表达CR5和IL-12可以增强CAR-T细胞的迁移,并克服瘤透巨细胞的免疫抑制.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
癌症治疗癌症治疗

背景情况:

固体瘤对CAR T细胞疗法构成挑战,包括透不良和免疫抑制瘤微环境.
像CCL4,CCL5和它们的受体CCR5这样的关键化学因子与瘤中T细胞透有关.
透瘤的巨细胞可以抑制CD8+ T细胞的抗瘤反应.

研究的目的:

通过解决透和免疫抑制,为固体瘤开发增强的CAR T细胞.
研究CCL4/CCL5-CCR5轴在CAR T细胞迁移中的作用.
评估IL-12分泌对抗巨细胞介导免疫抑制的潜力.

主要方法:

利用癌症基因组图谱数据库来识别关键的化学因子.
工程化针对美索林的CAR T细胞,以共同表达CCR5和IL-12 (CARTmeso-5-12).
在食道癌模型中评估工程CAR T细胞的体外和体外抗瘤能力.

主要成果:

在CAR T细胞中增强的CCR5表达改善了瘤透.
通过CAR T细胞分泌的IL-12减弱了巨细胞介导的免疫抑制.
CARTmeso-5-12细胞在体外和体内表现出优异的瘤根除能力.

结论:

在CAR T细胞中CCR5和IL-12的联合表达代表了克服固体瘤微环境障碍的有希望的策略.
这种双重工程的CAR T细胞方法增强了T细胞的迁移和功能,从而改善了瘤根除.

关键词:

在CAR T细胞中,CCR5 CCR5 的意思是什么?在IL-12中,IL-12是最重要的.瘤的镜子环境

更多相关视频

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...